Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Almirall S.A.
Industry Sector: HealthTechnology
CEO: Carlos Gallardo Piqué, MBA
Number Of Employees: 2,026
Enterprise Value: $1,826,854,920
PE Ratio: 211.27
Exchange/Ticker 1: Madrid:ALM
Exchange/Ticker 2: N/A
Latest Market Cap: $2,385,066,616
BioCentury | Mar 7, 2025
Management Tracks
Abbas Kazimi succeeds Jeb Keiper as CEO of Nimbus
Plus: Jon Garay Alonso named CFO of Almirall, and updates from Certara and Immunai
BioCentury | Mar 19, 2024
Deals
Deals Report: AZ buys Amolyt for Phase III asset, Novartis takes out IFM Due
Plus: Merck gains access to Pearl Bio’s synthetic biology platform for up to $1B, Hansoh partners with Biotheus on bispecific ADCs, and more
BioCentury | Feb 21, 2024
Distillery Therapeutics
Bivalent KEAP1 inhibitor for acute inflammatory diseases
BioCentury | Feb 21, 2024
Deals
Deal report: Astellas taps Kelonia for CAR Ts, Aurinia fails to find buyer, and more
Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and more
BioCentury | Nov 9, 2023
Deals
China’s strength is innovation on innovation. Western partners are lining up
Deep antibody expertise is a platform for leaps in new assets and technologies as Asia biotechs become increasingly competitive
BioCentury | Sep 22, 2023
Management Tracks
Shields leaving BenevolentAI as CEO
Plus: Berns named interim CMO at Faron, and updates from Coave, Maxion, Nanoscope and Patient Square
BioCentury | Sep 16, 2023
Data Byte
EMA agency suggests pulling Translarna, BlenRep from market
CHMP’s September opinions also include approval of seven new medicines and label extensions for 11
BioCentury | Sep 29, 2022
Deals
Sept. 29 Quick Takes: New life for Idera via Aceragen acquisition
Plus Biohaven’s verdiperstat misses again and updates from Meliora, Sarepta and more
BioCentury | Apr 13, 2022
Product Development
April 12 Quick Takes: FDA lifts clinical hold on magrolimab studies
Plus: Setback for Myovant at FDA and updates from Takeda, Ocugen, Prilenia, AbbVie and more
BioCentury | Apr 1, 2022
Product Development
Merck KGaA is avoiding big pipeline bets as it moves on from bintrafusp alfa
High risk-high reward replaced with well-defined activity in focused indications
Items per page:
1 - 10 of 299